What Researchers Did
Researchers retrospectively analyzed the efficacy and safety of hyperbaric oxygen therapy (HBOT) for chronic antibiotic-refractory pouchitis (CARP) and other inflammatory pouch conditions in 46 adult patients.
What They Found
They found a significant reduction in the mean Pouchitis Disease Activity Index (mPDAI) symptom subscore from 3.19 to 1.91 after HBOT (P < 0.05). Endoscopic subscores also significantly improved across the afferent limb, pouch body, and cuff (all P < 0.001 to P = 0.006), with transient side effects like ear barotrauma and myopic vision changes occurring in 5 patients (10.9%) each.
What This Means for Canadian Patients
For Canadian patients suffering from chronic antibiotic-refractory pouchitis, hyperbaric oxygen therapy may offer a new treatment option to alleviate symptoms and improve inflammation. This could potentially enhance quality of life for those who have not responded to conventional therapies, though further research is needed.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or patients.
Study Limitations
As a retrospective case series, this study is limited by its design, which inherently lacks a control group and may be subject to selection bias.